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The phosphatidylinositol-3-kinase (PI3K) and AKT (protein kinase B) signaling pathways play an important role in regulating cell cycle
progression and cell survival. In previous studies, we demonstrated that AKT is activated in HTLV-1-transformed cells and that Tax activation of
AKT is linked to p53 inhibition and cell survival. In the present study, we extend these observations to identify regulatory pathways affected by AKT
in HTLV-1-transformed cells. We demonstrate that inhibition of AKT reduces the level of phosphorylated Bad, an important member of the pro-
apoptotic family of proteins. Consistent with the decrease of phosphorylated Bad, cytochrome c is released from the mitochondria and caspase-9 is
activated. Pretreatment of the cells with caspase-9 specific inhibitor z-LEHD-FMK or pan caspase inhibitor Ac-DEVD-CHO prevented LY294002-
induced apoptosis. Of interest, p53 siRNA prevents LY294002-induced apoptosis in HTLV-1-transformed cells, suggesting that p53 reactivation is
linked to apoptosis. In conclusion, the AKT pathway is involved in targeting multiple proteins which regulate caspase- and p53-dependent apoptosis
in HTLV-1-transformed cells. Since AKT inhibitors simultaneously inhibit NF-κB and activate p53, these drugs should be promising candidates for
HTLV-1-associated cancer therapy.
Published by Elsevier Inc.Keywords: AKT; HTLV-1; apoptosis; LYZ9400Z; AKT inhibitor IIIntroduction
AKT, also known as protein kinase B (PKB), is a serine/
threonine kinase and the primary mediator of PI3K-initiated
signaling. AKT and upstream PI3K have a number of substrates
that contribute to malignant transformation (Chang et al., 2003)
and have been associated with diverse human cancers including
prostate, breast, lung, melanoma and leukemia (Lin et al., 1999;
Fry, 2001; Lin et al., 2001; Krasilnikov et al., 1999; Martinez-
Lorenzo et al., 2000; Nicholson and Anderson, 2002). AKT
plays a crucial role in a variety of cellular events such as
apoptosis, cell cycle progression and transcriptional regulation⁎ Corresponding author. Fax: +1 301 496 4951.
E-mail address: bradyj@exchange.nih.gov (J.N. Brady).
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doi:10.1016/j.virol.2007.09.003(Brazil et al., 2004). AKT's ability to prevent apoptosis in some
cells is established through phosphorylation and inhibition of
pro-apoptotic mediators such as Bad and caspase-9 (Datta et al.,
1999). In other situations, AKT activates the transcription factor
CREB, and the IκB kinase (IKK), a positive regulator of NF-κB,
to regulate the expression of genes with anti-apoptotic activity
(Fresno Vara et al., 2004). AKT also affects cell cycle pro-
gression by regulating cyclin D function. This is accomplished
by phosphorylation of p27 and p21 by AKT. Phosphorylation
restricts these proteins to the cytoplasm, effectively segregating
the cell cycle inhibitors from CDK–cyclin complexes (Collado
et al., 2000; Zhou et al., 2001).
Human T cell lymphotrophic virus type 1 (HTLV-1) is the
etiologic agent of adult T cell leukemia (ATL) and chronic
inflammatory diseases such as HTLV-1-associated myelopathy/
tropical spastic paraparesis (HAM/TSP) (Poiesz et al., 1980;
Seiki et al., 1983; Gessain et al., 1985; Osame et al., 1986).
265S.-J. Jeong et al. / Virology 370 (2008) 264–272HTLV-1 encodes a 40-kDa protein, Tax, which is critical for viral
replication, transformation and gene regulation (Akagi et al.,
1995; Grassmann et al., 1989; Nerenberg et al., 1987; Tanaka et
al., 1990). Tax interferes with cell growth control pathways
through direct interaction with regulatory proteins and regula-
tion of critical transcription pathways including NF-κB, CREB,
SRF, E2F and AP-1 (Xiao et al., 2001; Lemasson et al., 1998;
Iwai et al., 2001; Suzuki et al., 1999). Tax also inhibits the
transcription function of the tumor suppressor p53, inhibiting its
ability to respond to cellular stress signals (Cereseto et al., 1996;
Mulloy et al., 1998; Pise-Masison et al., 2001, 2000, 1998).
Furthermore, we have shown that Tax activates AKT, which isFig. 1. Effect of LY294002 on cell viability and cell cycle progression. (A) C81, Hut102
Cell viability was determined using theCellTiter-GloATP assay (Promega). (B) C81, Hut1
for 48 h. Cell viability was determined using the CellTiter-Glo ATP assay (Promega). (C
inhibitor II for 0, 24, 48, 72 or 96 h. Cell viability was determined using the CellTiter-Glinked to NF-κB activation, p53 inhibition and cell survival
(Jeong et al., 2005b).
The AKT signaling pathway is believed to contribute to the
maintenance of the latent state by suppressing apoptosis and
thereby preventing the elimination of virus-infected cells. Our
laboratory was the first to demonstrate that AKT is activated in
HTLV-1-transformed cells and is phophorylated at S473 and
T308 (Jeong et al., 2005b). These results were confirmed by
Ikezoe et al. who further showed that the upstream mTOR
pathway was activated in HTLV-1-transformed cells (Ikezoe et
al., 2007). In the present study, we extend these observations
to define downstream regulatory pathways which are regulatedandMT-2 cells (105 cells/ml) were treated with 20, 40 or 80 μMLY294002 for 72 h.
02 andMT-2 cells (105 cells/ml)were treatedwith 20, 40, or 80μMAKTinhibitor II
) C81, Hut102 and MT-2 cells (105 cells/ml) were treated with 20 or 40 μM AKT
lo ATP assay (Promega).
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strated that blocking AKT reduced phosphorylation of Bad,
increased cytochrome c release and activated the caspase-9
apoptosis pathway. Of interest, inhibition of p53 through an
adenovirus p53 siRNA demonstrated that p53 played an
important role in the apoptosis pathway induced by AKT
inhibition.
Results
Inhibition of AKT by LY294002 and AKT inhibitor II results in
cell death in HTLV-1-transformed cells
In previous studies, we demonstrated that Tax activates AKT
and that treatment of HTLV-1-transformed cells with LY294002
inhibited AKT activity (Jeong et al., 2005b). To gain a more
complete understanding of the importance of the activated AKT
pathway in HTLV-1-transformed cell lines, C81, MT-2 and
Hut102 were cultured with increasing concentrations of the
PI3K/AKT inhibitor LY294002. Cells were harvested and
analyzed for cell viability using the ATP CellTiter-Glo assay.
The results presented in Fig. 1A demonstrate that, upon
treatment with LY294002, cell viability decreased in a
concentration dependent manner (Fig. 1A). MT-2 and Hut102
were the most sensitive to the PI3K/AKT inhibitor followed by
C81 cells. In a parallel set of experiments, we determined that
cell death increased with time (data not shown). Thus, aFig. 2. (A) C81 cells (5×106 cells) were treated with 40 μM LY294002 for 0, 15 or 1
with propidium iodide solution and analyzed for cell cycle distribution by flow c
LY294002 for the times indicated. Cell lysates were prepared and western blot analy
Cruz), cyclin D1 (Cell Signalling) and cyclin E (Santa Cruz) as visualized by chemconcentration- and time-dependent cell death response to
LY294002 treatment was observed.
To provide further evidence for the role of AKT in HTLV-1 in
cell survival, we analyzed the effect of specific AKT inhibitor II.
The inhibitor is a phosphatidylinositol analog that inhibits the
activation of AKT without decreasing phosphorylation of
upstream kinase PDK-1. C81, Hut102 and MT-2 cells were
incubated with 0, 20, 40 or 80 μM AKT inhibitor II for 48 h.
Cells were harvested and analyzed for cell viability using the
ATP CellTiter-Glo assay. The results presented in Fig. 1B
demonstrate that inhibition of AKT leads to a dose-dependent
increase in cell death. We next determined if cell death was time
dependent. C81, Hut102 and MT2 cells were treated with AKT
inhibitor II at a concentration of 20 or 40 μM. An aliquot of cells
was harvested at 0, 24, 48, 72 and 96 h and analyzed for cell
viability using the ATP CellTiter-Glo assay. The results
presented in Fig. 1C demonstrate that there was a time-
dependent increase in cell death following treatment with the
specific AKT inhibitor. Because of the cost of AKT inhibitor II,
all subsequent studies were done with AKT inhibitor LY294002.
Alteration in cell cycle and p27 expression following inhibition
of AKT
We next analyzed the effect of AKT inhibition on cell cycle
distribution by FACS analysis. Cell cycle analysis of the C81,
MT-2 and Hut102 cells following treatment with LY2940028 h. Cells were harvested, fixed in 70% ethanol, treated with RNase and stained
ytometry. (B/C) C81 or Hut102 cells (5×106 cells) were treated with 40 μM
sis was performed to detect the expression of p27 (Cell Signalling), p21 (Santa
iluminescence.
Fig. 3. Effect of LY294002 on Bad phosphorylation and cytochrome c release.
(A) C81 cells (5×106 cells) were treated with 40 μMLY294002 for 0, 3, 9 or 18 h.
Cell lysates were prepared and western blot analysis was performed to detect the
expression of phospho-Bad (Ser136), Bad, Bax, phospho-AKT (Ser473) and AKT
(Cell Signaling) as visualized by chemiluminescence. (B) C81 cells were cultured
with or without 40 μM LY294002 for 18 h for analysis of cytochrome c release.
Confocal microscopy shows mitochondrial location of cytochrome c (upper panel)
and DAPI staining (lower panel) in control cells and cytosolic translocation in
LY294002-C81 treated cells.
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sub-G1 cells (Fig. 2A; data not shown). By 18 h after treatment
with LY294002, the percentage of cells in sub-G1 increased
from 2.7 to 21%. A similar increase in the percentage of sub-G1
cells was observed in the analysis of MT-2 and Hut102 cells
(data not shown). We also noted that the percentage of cells in
G1 increased by 18 h post treatment (Fig. 2A).
Consistent with the accumulation of cells in G1, western blot
analysis of C81 cell extracts demonstrated that the level of cdk
inhibitor p27 increased dramatically, while the level of cyclin
D1 decreased (Fig. 2B). A similar increase in p27 protein was
observed following treatment of Hut102 cells with AKT
inhibitor LY294002 (Fig. 2C). While the increase in p27
protein is under investigation, the decrease in cyclin D1
expression is likely the result of inhibition of the NF-κB
signaling pathway by LY294002 (Joyce et al., 1999; Hinz et al.,
1999; Guttridge et al., 1999; Jeong et al., 2005b). In contrast to
these two proteins, the level of p21 and cyclin E remained
relatively constant throughout the treatment (Fig. 2B). The level
of control protein actin remained constant throughout the time
course (Fig. 2B).
Analysis of Bcl-2 family members, Bad phosphorylation and
cytochrome c release following treatment with LY294002
To gain greater insight into the apoptosis pathway induced by
LY294002, we analyzed the protein expression of Bcl-2 family
members including pro-apoptotic Bad and Bax. Since all the
HTLV-1-transformed cell lines had reacted similarly to the AKT
inhibitors, we chose C81 cells for a more in depth mechanistic
analysis. HTLV-1-transformed C81 cells were treated with
LY294002 for 0, 3, 9 or 18 h and cell extracts were prepared for
western blot analysis. As shown in Fig. 3A, while the overall
level of Bad protein remained constant a significant decrease in
the level of phosphorylation of Bad at Ser136 was observed.
Consistent with previous results and as a control for these
studies, AKT phosphorylation at Ser473 decreased with time
and total AKTwas constant (Fig. 3A, lower panels) (Jeong et al.,
2005b). A similar decrease in AKT phosphorylation at Thr308
was observed in these experiments (data not shown), consistent
with previous findings (Jeong et al., 2005a).
Phosphorylation of Bad at Ser136 inhibits the pro-apoptotic
function of the protein by decreasing its interaction with Bcl-xL
on the mitochondrial membrane. Given the decrease in Bad
phosphorylation observed above, immunofluorescent staining
of cytochrome c was conducted with C81 cells in the absence or
presence of LY294002. Confocal microscopy revealed that, in
untreated cells, cytochrome c was localized in a punctate pattern
consistent with localization in the mitochondria (Fig. 3B, top
left). In contrast, after treatment with LY294002, a diffuse
distribution of cytochrome c was observed (Fig. 3B, top right).
The later staining pattern is consistent with the release of
cytochrome c from the mitochondria to the cytosol. Control
immunofluorescent assays with control IgG revealed no staining
of the control or treated cells (data not shown). We further
analyzed cytochrome c distribution bywestern blot analysis. The
results of these studies demonstrated that the level of cytosoliccytochrome c was significantly increased in the LY294002-
treated cells (data not shown).
LY294002-induced apoptosis is dependent on activity of
caspase-9 in HTLV-1-transformed cells
Release of cytochrome c from the mitochondria is associated
with caspase-9 activation (Garrido et al., 2006). Moreover, AKT
also directly inhibits the proteolytic activity of caspase-9 by
phosphorylation of the protein at Ser136 (Cardone et al., 1998).
It was important, therefore, to test whether caspase-9 was
activated in the LY294002-treated cells. To test the activation of
caspase-9 in LY294002-induced apoptosis, we carried out
chemiluminescent assays that specifically measure caspase-9
activity. LY294002 induced caspase-9 activation in a dose-
dependent manner (Fig. 4A). Consistent with these findings, we
observed the reduction of full-length caspase-9 protein follow-
ing LY294002 treatment (Fig. 4B). Coincident with the
disappearance of full-length caspase-9, we observed the
appearance of lower molecular weight cleavage products (data
not shown). Trypan blue dye exclusion assays confirmed the
importance of caspase-9 in the apoptosis pathway (Fig. 4C).
LY294002 treatment induced apoptosis in a time-dependent
manner, with approximately 50% of the cells undergoing
apoptosis by 72 h in this experiment. Pretreatment of the cells
with either the caspase-9 specific or pan-specific inhibitor
significantly reduced LY294002-induced apoptosis (Fig. 4C).
Fig. 4. LY294002-induced apoptosis is dependent on caspase-9 activity in HTLV-1-
transformed cells. (A) Caspase-9 activity was measured by using Caspase Glo-9
assay systems (Promega). C81 cells (5×106 cells) were treated with 40 μM
LY294002 for 24 h and harvested by centrifugation and supernatants were collected.
Samples were gently mixed with Caspase Glo substrate and the luminescence of
each sample was measured by using the Luciferase assay system. Error bars were
calculated using three independent experiments. (B) Lysates were prepared from
control or 40 μM LY294002-treated C81 cells and western blot analysis was
performed to detect the expression of caspase-9 (Cell Signaling) as visualized by
chemiluminescence. (C) C81 cells were treated with caspase inhibitors (100 μM)
z-LEHD-FMKorAc-DEVD-CHO for 1 h prior to treatment with 40μMLY294002
for 0 to 72 h. Apoptosis was determined by the percentage of trypan blue positive
cells.
Fig. 5. LY294002 or SC-514-induced apoptosis is p53-dependent pathway in
HTLV-1-transformed cells. (A) C81 cells were infected with Ad-p53 siRNA or Ad-
GFP in the absence or presence of 40 μM LY294002. After 72 h, cell lysates were
prepared and western blot analysis was performed to detect the expression of p53
(Oncogene), phospho-AKT (Ser473) and AKT (Cell Signaling) as visualized by
chemiluminescence. (B) Trypan blue dye exclusion assays were performed to
measure apoptosis. C81 cells were infected with Ad-GFP or Ad-p53 siRNA in
serum-free media. After 3 h, cells were harvested and resuspended in serum-
containing media and 40 μM LY294002 was added for indicated times.
268 S.-J. Jeong et al. / Virology 370 (2008) 264–272Together, the results suggest that LY294002-induced apoptosis
involves the Bad/cytochrome c/caspase-9 mitochondria-depen-
dent pathway.
LY294002 or SC-514-induced apoptosis is a p53-dependent
pathway in HTLV-1-transformed cells
p53, through its activity as a transcriptional activator or
repressor, functions as a tumor suppressor inducing either cell
cycle arrest or apoptosis in response to cellular stress (Oren,
2003; Vousden and Lu, 2002). Previous studies from this
laboratory demonstrated that AKTactivation plays a critical role
in the inhibition of p53 function in HTLV-1-transformed cells as
treatment of C81 cells with LY294002 reactivated p53
transcription activity as measured by MDM2 promoter activity
(Jeong et al., 2005b). Therefore, we tested whether p53 plays a
role in the LY294002-induced apoptosis. C81 cells were infectedwith Ad-GFP or Ad-p53 siRNA in the absence or presence of
LY294002. As shown in Fig. 5A, infection of the cells with Ad-
p53 siRNA significantly reduced p53 expression in the absence
or presence of LY294002 (lanes 1, 3, and 4). In contrast,
infection of cells with the control Ad-GFP virus did not affect
p53 expression (lanes 1 and 2). As a control for these studies, we
demonstrate that while LY294002 inhibited the phosphorylation
of AKT, expression of AKT protein was not significantly
affected by the infection with the Ad-GFP or Ad-p53 siRNA
expressing virus (Fig. 5A, middle and bottom panel). These
results are consistent with previous studies using the p53 siRNA
which demonstrated that the Ad-p53 siRNA specifically inhibits
expression of p53, but not other cellular genes (Zhao et al.,
2003). The Ad-GFP virus infection serves as a control for any
effect of adenovirus infection that may affect the experiment.
Consistent with the results presented above, treatment of the
cells with LY294002 decreased the level of phospho-AKT
(S473). The decrease in AKT phosphorylation was similar in the
Ad-p53 siRNA and Ad-GFP infected cells.
Lastly, trypan blue assays were used to measure cell viability
with Ad-p53 siRNA infected C81 cells in the absence or
presence of LY294002 (Fig. 5B). In these studies, we also
included cells which were treated with IKKβ specific inhibitor
SC-514 (Kishore et al., 2003). IKKβ was targeted since it is a
direct substrate of AKT and plays an important role in NF-κB
activation and inhibition of p53 in HTLV-1-transformed cells
(Jeong et al., 2005a). The results of these experiments
demonstrate that infection of C81 cells with Ad-GFP or Ad-
p53 siRNA caused a modest increase in cell death (Fig. 5B).
Addition of LY294002 or SC-514 to the control Ad-GFP
infected cells resulted in a 3- to 5-fold increase in cell death. In
contrast, addition of LY294002 or SC-514 to cells infected with
269S.-J. Jeong et al. / Virology 370 (2008) 264–272Ad-p53 siRNA did not result in a significant increase in cell
death. These results suggest that blocking AKT activation or its
downstream target IKKβ leads to the induction of a p53-
dependent apoptosis in C81 cells.
Discussion
Activation of the AKT pathway is common in many cancers
and contributes to the inhibition of apoptosis and therapeutic
resistance through multiple mechanisms (Nuutinen et al., 2006).
Consistent with these observations, inhibition of AKT decreases
cell survival and potentiates the effects of chemotherapeutic
drugs in cancer cells (Clark et al., 2002; Asselin et al., 2001b,a).
We and others have shown that AKT is activated in HTLV-1-
transformed cells and plays an important role in cell survival. In
part, the importance of AKT to cell survival is due to the
regulation of multiple target pathways through phosphorylation
of critical proteins. For example, phosphorylation of Bad by
AKT inactivates the protein's ability to induce apoptosis, thus
promoting cell survival. Conversely, dephosphorylation of Bad
results in targeting of Bad to mitochondrial membranes where
Bad interacts with and inactivates anti-apoptotic proteins Bcl-2
and Bcl-xL, inducing apoptosis (Datta et al., 1999). We have
previously shown that HTLV-1 Tax mediates activation of AKT
by mediating phosphorylation at Ser473 and Thr308 (Jeong et
al., 2005b). In the present study, we demonstrate that blocking
AKT by LY294002 decreased the phosphorylation of Bad. Since
Bad regulates the mitochondrial release of cytochrome c
(Yamaguchi et al., 2001), cytochrome c localization was
analyzed in C81 cells in the absence or presence of
LY294002. Release of cytochrome c was observed both by
immunofluorescent staining and western blot analysis (data now
shown) of fractionated cell extracts. The best-defined target for
cytochrome c is the apoptosomewhich is amultiprotein complex
comprising Apaf-1, cytochrome c and caspase-9 that activates
the apoptotic pathway (Zou et al., 1999). In our studies, cleavage
of caspase-9 was induced by LY294002 and pretreatment with a
caspase-9 specific or pan caspase inhibitor significantly blocked
LY294002-induced apoptosis (Fig. 4C). These results suggest
that, in HTLV-1-transformed cells, LY294002 induces apoptosis
which is dependent on the dephosphorylation of Bad and
activation of caspase-9.
Recent studies have demonstrated that AKT is also a
signaling intermediate upstream of NF-κB dependent survival
gene expression (Datta et al., 1999). NF-κB activation requires
phosphorylation of IκBα by IκB kinases (IKKs). IκBα
phosphorylation targets IκBα for ubiquitination and proteolytic
degradation (Baldwin, 1996; Beg and Baldwin, 1993), releasing
p50–p65 heterodimers to migrate to the nucleus and activate
transcription. It has been shown that IKKs are a substrate of AKT
and its ability to regulate NF-κB activity may be through direct
interaction with IKKs as AKT can associate with the IKK
complex in vivo (Datta et al., 1999). In the present study, C81
cells were treated with SC-514, an IKKβ specific inhibitor
(Kishore et al., 2003). SC-514 induced apoptosis in HTLV-1-
transformed cells to a level similar to that obtained with
LY294002 treatment. Previous data from our laboratory haveshown that LY294002 or SC-514 induced p53-dependent
transcription. These results and data presented here argue that
the AKT/IKKβ pathway plays a critical role in NF-κB activation
and cell survival in HTLV-1-transformed cells.
Inactivation of the tumor suppressor protein p53 plays a
critical role in tumorigenesis. p53 functions as an integrator of
stress response signals by activating or repressing the
transcription of genes that regulate cell cycle progression and/
or apoptosis (Appella and Anderson, 2001; Giaccia and Kastan,
1998; Meek, 1999; Prives and Hall, 1999). Over the past several
years, it has become evident that p53 and AKT are involved in a
complex cross-talk that are at the core of the cell control
machinery for switching between survival and death. This
cross-talk is a combination of reciprocally antagonistic path-
ways emanating from p53 and AKT, which also involve tumor
suppressor gene, PTEN, and oncogene, Mdm2 (Wee and
Aguda, 2006). We investigated whether p53 plays a role in the
regulation of LY294002-mediated apoptosis and cell cycle
arrest in HTLV-1-transformed cells. An adenovirus vector
expressing a siRNA to p53 was utilized to specifically decrease
expression of p53. The results of these studies clearly
demonstrate that the Ad-p53 siRNA decreased LY294002-
induced apoptosis. Thus, while activation of Bad and caspase-9
occurs in response to AKT inhibition, they are not sufficient to
induce apoptosis, but must signal through the p53 pathway to
induce apoptosis.
In a recent paper, Peloponese et al. suggested that Tax, in the
absence of NF-κB activation, can activate activator protein-1
(AP-1) to promote cellular proliferation and survival through the
PI3K/AKT pathway (Peloponese and Jeang, 2006). These
results are not inconsistent with our data, but focus more on
the role of Tax-activated AKT in cell proliferation and provide
intriguing data that Tax activates AKT through direct interaction
with the p85 subunit of PI3K.
Following our original observation that AKTwas activated in
HTLV-1-transformed cells, Ikezoe et al. (2007) reported that the
PI3K/AKT/mammalian target of rapamycin (mTOR) was
activated in HTLV-1 cells. The authors demonstrated that
rapamycin, the inhibitor of mTOR, induced growth inhibition
and cell cycle arrest. Interestingly, the authors demonstrated that
PI3K/AKT inhibitor LY294002 exhibited similar properties,
inhibiting cell growth and inducing cell cycle arrest. When
rapamycin was combined with LY294002, the ability of
rapamycin to induce growth arrest and cause dephosphorylation
of p70S6K and 4E-BP-1 was potentiated. It was suggested that
the effect of LY294002 was due to its ability to block
phosphorylation of AKT at Ser473, which was paradoxically
induced by rapamycin.
In the present paper, we demonstrate that in HTLV-1-
transformed cells AKT regulates pathways involved in cell cycle
and cell viability. AKT phosphorylates or induces the phos-
phorylation of Bad, decreasing its ability to interact with and
inhibit the function of Bcl-xL (Fig. 6). AKTalso induces NF-κB,
which increases expression of Bcl-xL, an inhibitor of apoptosis.
AKT regulates cell cycle progression through regulation of p27
and cyclin D1.While AKT likely regulates cyclin D1 expression
through NF-κB, its interaction with p27 requires further
Fig. 6. HTLV-1 Tax activation of AKT regulates cell survival through multiple
targeting molecules. Tax activates AKT in HTLV-1-transformed cells through the
PI3 kinase pathway. Blocking AKT function using LY294002 results in decreased
phosphorylation of Bad, cytochrome c release, caspase-9 activation and apoptosis.
LY294002 treatment also blocks AKT dependent phosphorylation of the IKKβ,
resulting in a decrease in NF-κB binding and transcription activity. Apoptosis is
dependent upon p53 activity as indicated by the ability of an siRNA to p53 to inhibit
apoptosis.
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targeting AKT and its downstream molecules in other human
cancers. LY294002 effectively inhibits the growth of many types
of tumor cells in vitro and in vivo and combining LY294002
with conventional chemotherapeutic agents may provide a
treatment option for drug-resistant cancers. Poor solubility and
high toxicity of LY294002 have stimulated the development of
derivatives or specific AKT inhibitors including PX-866,
IC486068, helenaquinone, perifosine and PX-316. AKT
antagonist API-2 (AKT/PKB signaling inhibitor-2) has been
shown to inhibit AKT kinase activity and to induce apoptosis in
human cancer cells with high AKT activity (Yang et al., 2004).
The results of this study suggest that these compounds may be
considered useful in the treatment of ATL patients.
Materials and methods
Cell culture and drug treatment
HTLV-1-transformed C81 cells were maintained in RPMI
supplemented with 10% fetal calf serum, 2 mM L-glutamine and
penicillin (100 units/ml)/streptomycin (100 μg/ml). For treat-
ment with LY294002, 5×106 cells were cultured in 10 ml of
media in 100 mm dishes for the indicated times. Caspase
inhibitors z-LEHD-FMK (100 μM) or Ac-DEVD-CHO
(100 μM) were added 1 h prior to addition of LY294002. All
drugs were obtained from Calbiochem.
LY294002 and AKT inhibitor II
AKT inhibitor LY294002 is a cell permeable, potent and
specific phosphatidylinositol 3-kinase inhibitor that acts in theATP binding site of the enzyme. AKT inhibitor II is a
phosphatidylinositol analog that inhibits the activation of
AKT without decreasing phosphorylation of upstream PDK-1.
Western blot analysis
Whole cell extracts were prepared by using lysis buffer
(50 mM Tris–HCl pH 7.4, 120 mM sodium chloride, 5 mM
EDTA, 0.5% Nonidet P-40, 50 mM sodium fluoride, 0.2 mM
sodium vanadate and complete protease inhibitor from Roche
Diagnostics) at a cell concentration of 107 cells/ml. The extracts
were incubated on ice for 15 min, centrifuged (10,000×g) at
4 °C for 10 min, and supernatants were collected. Protein
concentrations were determined by Bradford assay (Bio-Rad),
and 50–100 μg protein was separated by electrophoresis in 4 to
20% Tris–glycine gels (Novex). The proteins were then
transferred to PVDF membranes (Immobilon) and western
blot analysis performed with the indicated antibodies. Phospho-
Bad (Ser136), Bad, Bax, phospho-AKT (Ser473), AKT,
Caspase-9, p27 and cyclin D1 antibodies were obtained from
Cell Signaling. p21 and Cyclin E antibodies were obtained from
Santa Cruz Biotechnologies.
Immunofluorescent staining
Following treatment with LY294002 (40 μM), C81 cells were
placed on lysine coated coverslips, fixed in PBS-buffered 4%
paraformaldehyde and permeabilized in cold methanol. The
permeabilized cells were incubated with 10% normal goat serum
in PBS for 1 h followed by immunostaining with anti-
cytochrome c antibody (Active Motif) and an Alexa Fluor
488-conjugated anti-mouse IgG antibody. The immunostained
cells were mounted in mounting medium containing DAPI
(Vectashield, Vector Labs) and were visualized by a Leica
confocal microscope.
Cell viability
Cell viability was determined either by trypan blue staining
or the CellTiter-Glo ATP assay. In the trypan blue assay, cells
were stained with 0.4% trypan blue solution (Quality Biotech)
for 1 min. Cells that took up trypan blue were counted as dead
cells and expressed as a percentage of the total cell number.
Alternatively, cell viability assay was determined using Cell-
Titer-Glo luminescent cell viability assay from Promega using
the manufacturer's instruction. Briefly, 1–2×105 cells were
cultured in sterile 96 well culture plates in the presence of
appropriate concentration of LY294002 (20–80 μM) in 100 μl
of RPMI media. The plates were then incubated for the time
indicated. One hundred microliters of CellTiter-Glo reagent was
added to lyse the cells. The contents were mixed in an orbital
shaker for 2 min and then incubated at room temperature for
10 min. The luminescence was then recorded in a luminometer
with an integration time of 1 s per well. The luminescent signals
for the LY294002-treated cells were normalized to the lumi-
nescent signal of cells treated with DMSO which was arbitrarily
set to 1.
271S.-J. Jeong et al. / Virology 370 (2008) 264–272Analysis of caspase-9 activity
Caspase-9 activity was measured by using Caspase Glo-9
assay systems (Promega). Briefly, C81 cells (5×106 cells/10 ml)
were treated with 40 μM LY294002 for 24 h. Cells were
harvested by centrifugation and supernatants were collected.
Samples (100 μl) were gently mixed with Caspase Glo substrate
(100 μl) and the luminescence of each sample was measured by
using Luciferase assay system (Promega).
Adenovirus infection of cells
The pAdTrack-si/p53 (Ad-p53 siRNA) construct was kindly
provided by Dr. Ling-Jun Zhao (St. Louis University) and pAd-
GFP was purchased from Q-Biogene. The recombinant viral
genome was linearized with PacI and transfected into 293 cells
in a 60-mm dish using PolyFect transfection reagent (Qiagen).
Eight days after transfection, the recombinant virus was
collected and subjected to one round of amplification by
infecting 1.5×106 293 cells, yielding 2 ml of viral stocks.
Infection of 293 cells was performed in serum free DMEM.
Following viral infection, 293 cells were maintained in DMEM
with 10% fetal bovine serum. HTLV-1-transformed C81 cells
(1.5×106) in a 60-mm dish were infected with either Ad-p53
siRNA or Ad-GFP in serum-free RPMI media. After 3 h, cells
were resuspended in media containing 10% fetal calf serum.
LY294002 (40 μM) was added and incubations carried out at as
indicated.
Cell cycle analysis
Adenoviral infected C81 cells with or without LY294002
were harvested and fixed in 70% ethanol. The fixed cells were
then stained with propidium iodide (50 μg/ml) after treatment
with RNase (5 μg/ml). The stained cells were analyzed for DNA
content in FACSCalibur (Becton Dickinson) using the Cell
Quest program (Becton Dickinson). The resultant data were
analyzed by ModFit LT (Verity Software House) using appro-
priate gates.
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